FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic

MONDAY, April 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.

Several hundred units of Ozempic injection 1 mg have found their way into the drug supply chain in the United States. The seized counterfeit products display a combination of lot number PAR0362 (an authentic lot number) and illegitimate serial numbers that begin with the following eight digits: 51746517. Only products with this lot number coupled with the erroneous serial number are considered counterfeit products.



Javascript is required for you to be able to read premium content. Please enable it in your browser settings..